New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 4, 2012
09:12 EDTDTEGY, S, PCS, MTN, PBY, ESIO, TEVA, GALE, TOL, BIG, DRIOn The Fly: Pre-market Movers
HIGHER AFTER EARNINGS: Big Lots (BIG), up 7.3%... Toll Brothers (TOL), up 4.6%... ALSO HIGHER: Galena Biopharma (GALE), up 15% after signing NeuVax commercialization partnership with Teva (TEVA)... Electro Scientific (ESIO), up 12% after declaring $2/share special dividend... LOWER AFTER EARNINGS: Pep Boys (PBY), down 8.7%... Vail Resorts (MTN), down 7.3%... ALSO LOWER: Darden (DRI), down 8.9% after warning on Q2, FY13 EPS... MetroPCS (PCS), down 6.6% after Reuters says Sprint (S) unlikely to counter T-Mobile's (DTEGY) bid.
News For DRI;BIG;TOL;GALE;TEVA;ESIO;PBY;MTN;PCS;S;DTEGY From The Last 14 Days
Check below for free stories on DRI;BIG;TOL;GALE;TEVA;ESIO;PBY;MTN;PCS;S;DTEGY the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
July 23, 2014
10:02 EDTTEVAOn The Fly: Analyst Initiation Summary
Subscribe for More Information
08:10 EDTTEVADeutsche Bank hosts an analyst Specialty Pharma/Industry conference call
Subscribe for More Information
July 22, 2014
16:08 EDTTEVATeva initiated with a Buy at Deutsche Bank
Subscribe for More Information
15:46 EDTGALEGalena in-license of Zuplenz makes sense, says Piper Jaffray
Subscribe for More Information
09:55 EDTGALEGalena 'stands little chance' of improving Zuplenz sales, TheStreet says
After Galena BioPharma entered into a license agreement with MonoSol Rx for Zuplenz, TheStreet's Adam Feuerstein predicted that the company "stands little chance of delivering higher sales of Zuplenz than its previous marketer," calling the drug one that "no one wants" and "something to promote while waiting for the phase III study of NeuVax in breast cancer to inevitably fail." Reference Link
07:21 EDTGALEGalena enters into licensing agreement with MonoSol Rx
MonoSol Rx announced that it has licensed Zuplenz to Galena Biopharma. Zuplenz is an oral soluble film, or OSF, for the prevention of chemotherapy-induced, radiotherapy-induced, and postoperative nausea and vomiting. The licensing agreement includes an undisclosed upfront payment from Galena, as well as double digit royalty payments from sales of Zuplenz. Zuplenz is the first oral soluble lingual film product approved by the FDA as a prescription medication, based on MonoSol Rx's proprietary PharmFilm technology.
July 21, 2014
08:11 EDTTEVAArena Pharma' subsidiary enters into agreement for Belviq with Teva subsidiary
Subscribe for More Information
08:01 EDTTEVATeva completes acquisition of Labrys
Subscribe for More Information
07:45 EDTSSprint consensus estimates 'overly optimistic,' says Jefferies
Subscribe for More Information
July 20, 2014
14:47 EDTSAfter paring Mexican assets Carlos Slim may look at T-Mobile, WSJ says
Subscribe for More Information
July 18, 2014
10:38 EDTPBYAutoZone, O'Reilly drop following Stifel downgrades
Subscribe for More Information
09:18 EDTDTEGY, SSoftbank hire of Arora from Google 'interesting,' says Wells Fargo
Subscribe for More Information
07:08 EDTDTEGY, SSoftbank, T-Mobile final agreement could come after late August, Kyodo News says
According to Kyodo News, Softbank's (SFTBF) buyout talks with T-Mobile (TMUS) won't be settled until after late August. Deutsche Telecom (DTEGY) is "reluctant" to accept Softbank's business plan and is seeking a new plan, industry sources say. Reference Link
July 16, 2014
18:26 EDTDRIOn The Fly: After Hours Movers
Subscribe for More Information
08:48 EDTTEVATeva says ISS supports company's nominees, shareholders' meeting proposals
Subscribe for More Information
July 15, 2014
15:32 EDTSPaulson sees T-Mobile takeover in high $30s, low $40s 'reasonable,' WSJ says
John Paulson, the fourth-largest shareholder in T-Mobile (TMUS) and the third largest stakeholder in Sprint (S), would support a merger of the two, which has been widely reported as being worked on, and said that a takeover price for T-Mobile in the "high $30s to low $40s" per share would be "reasonable," according to The Wall Street Journal, citing an interview with the investor. Reference Link
13:44 EDTSSprint, T-Mobile jointly raising $10B for airwave auction, WSJ says
Subscribe for More Information
13:20 EDTDRIStarboard sends letter to Darden board seeking new leadership
Subscribe for More Information
11:13 EDTTEVAPerrigo retreats after analyst sees limited potential buyers
Subscribe for More Information
06:28 EDTTEVAActivist shareholder says Teva to appoint new chairman, Reuters says
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use